(Q37199322)

English

Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine

scientific article published on July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1 reference

Europe PubMed Central

Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

author name string

C Bradley

1

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

C J B Gilbride

2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

publication date

1 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

10 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

50-65

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Patient perceptions of diabetes and diabetes therapy: assessing quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Usefulness of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) questionnaire in patients with diabetes in a multi-ethnic Asian country.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Emotional and quality-of-life aspects of diabetes management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Patient-assessed health outcome measures for diabetes: a structured review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Development and validation of the insulin treatment satisfaction questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Treatment satisfaction after commencement of insulin in Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

The influence of diabetic retinopathy on quality of life: interviews to guide the design of a condition-specific, individualised questionnaire: the RetDQoL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Development and validation of the Diabetes Quality of Life Clinical Trial Questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

The well-being questionnaire: evidence for a three-factor structure with 12 items (W-BQ12).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Psychometric evaluation of the 12-item Well-being Questionnaire for use with people with macular disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Importance of differentiating health status from quality of life.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Problems with the performance of the SF-36 among people with type 2 diabetes in general practice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Exenatide: a new option for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Fear of hypoglycemia: quantification, validation, and utilization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Effect on quality of life with a new insulin injection device in elderly patients with diabetes mellitus type 2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mell

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Preference for insulin delivery systems among current insulin users and nonusers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Effect of insulin therapy on quality of life in Type 2 diabetes mellitus: The Fremantle Diabetes Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00871.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2008.00871.X

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37199322&oldid=2185916919"